<div id="readability-page-1"><p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report)'s share price dropped 3.9% during mid-day trading on Thursday following insider selling activity. The stock traded as low as $37.47 and last traded at $37.2550. Approximately 120,139 shares traded hands during trading, a decline of 84% from the average daily volume of 729,320 shares. The stock had previously closed at $38.78.</p><div><p><span></span><span>Get <strong>Harmony Biosciences</strong> alerts:</span></p></div><p>Specifically,  CEO Jeffrey M. Dayno sold 25,933 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. </p><h2>Wall Street Analyst Weigh In</h2><p>Several analysts have issued reports on the company. Wall Street Zen raised Harmony Biosciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, December 13th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Harmony Biosciences from $54.00 to $36.00 and set a &#34;buy&#34; rating for the company in a report on Thursday, September 25th. Oppenheimer  reaffirmed an &#34;outperform&#34; rating and set a $62.00 target price on shares of Harmony Biosciences in a report on Monday, November 24th. Mizuho lifted their target price on shares of Harmony Biosciences from $39.00 to $46.00 and gave the stock an &#34;outperform&#34; rating in a research report on Monday, December 1st. Finally, Needham &amp; Company LLC  restated a &#34;buy&#34; rating and set a $42.00 price target on shares of Harmony Biosciences in a research report on Monday, November 24th. One analyst  has rated the stock with a Strong Buy rating, seven have assigned  a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $45.63.</p><p><b>View Our Latest Research Report on Harmony Biosciences</b></p><h2>Harmony Biosciences Stock Down 3.1%</h2><p>The stock's fifty day moving average is $32.73 and its 200 day moving average is $33.38. The company has a market capitalization of $2.16 billion, a P/E ratio of 11.75, a price-to-earnings-growth ratio of 0.49 and a beta of 0.80. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18. </p><p>Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.05). The firm had revenue of $239.46 million for the quarter, compared to analysts' expectations of $222.68 million. Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%. Research analysts predict that  Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year. </p><h2>Hedge Funds Weigh In On Harmony Biosciences</h2><p>Hedge funds have recently made changes to their positions in the business. Strs Ohio purchased a new position in  Harmony Biosciences during the 1st quarter valued at $587,000.  Robeco Institutional Asset Management B.V. bought a new stake in shares of  Harmony Biosciences during the 2nd quarter valued at about $1,478,000.  Capital Fund Management S.A. purchased a new position in shares of  Harmony Biosciences during the second quarter valued at about $1,142,000.  CX Institutional raised its stake in  Harmony Biosciences by 166.8% in the second quarter. CX Institutional now owns 207,783 shares of the company's stock worth $6,566,000 after buying an additional 129,916 shares in the last quarter.  Finally, Woodline Partners LP purchased a new stake in  Harmony Biosciences in the first quarter worth about $6,035,000. 86.23% of the stock is owned by hedge funds and other institutional investors. </p><h2>Harmony Biosciences Company Profile</h2> (Get Free Report)<p>Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Harmony Biosciences</li><li>What is Short Interest? How to Use It</li><li>3 Cheap Dividend Stocks That Can Beat Inflation and Pay You to Wait</li><li>How to Calculate Retirement Income: MarketBeat’s Calculator</li><li>3 New Year’s Resolution Stocks That Could Turn Around in 2026</li><li>Asset Allocation Strategies in Volatile Markets</li><li>Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Harmony Biosciences Right Now?</h2><p>Before you consider Harmony Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.</p><p>While Harmony Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HRMY

<p>Harmony Biosciences' stock (NASDAQ:HRMY) fell 3.9% after CEO Jeffrey M. Dayno sold 25,933 shares. The stock traded at a low of $37.47, with a significant drop in trading volume. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a target price of $45.63. The company reported lower-than-expected earnings for the last quarter. Hedge funds have been adjusting their positions in the company.</p>

Harmony Biosciences (NASDAQ:HRMY) Trading Down 3.9% After Insider Selling